Показати скорочений опис матеріалу
dc.contributor.author | Shkarupa, V. M. | en |
dc.contributor.author | Klymenko, S. V. | en |
dc.date.accessioned | 2018-10-23T10:04:33Z | |
dc.date.available | 2018-10-23T10:04:33Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Shkarupa V. M. Radioprotective properties of sodium humate in radiation-induced mutagenesis in cultured lymphocytes of thyroid cancer patients / V. M. Shkarupa, S. V. Klymenko // Experimental Oncology. - 2016. - № 38. - P. 108-111. | en |
dc.identifier.uri | https://dspace.vnmu.edu.ua/123456789/3110 | |
dc.description.abstract | Aim: To investigate the effect of sodium humate on the level of cytogenetic damage in culture of lymphocytes of patients with thyroid cancer after γ-irradiation. Materials and Methods: Metaphase analysis of chromosome aberrations in cultured peripheral blood lymphocytes of 10 individuals with thyroid cancer was performed after irradiation of lymphocytes in vitro at a dose of 1 Gy from 137Cs source at the early G0 phase of cell cycle. Sodium humate was added to cell culture for 30 ± 15 min after phytohemagglutinin stimulation at concentrations of 10 and 100 μg/ml. Results: Sodium humate exhibited antimutagenic properties. The preparation at a concentration of 10 μg/ml was more effective than at a concentration of 100 μg/ml, reducing the average incidence of radiation-induced chromosome aberrations by 51.88 and 38.77%, respectively. The most pronounced antimutagenic effect of sodium humate was the reduction of the frequency of chromosomal type aberrations, however, such efficiency varied between individual patients with thyroid cancer. Conclusions: Sodium humate could be considered as a potential therapeutic modifier of radiation damage. | en |
dc.language.iso | en | en |
dc.subject | thyroid cancer | en |
dc.subject | γ-irradiation | en |
dc.subject | chromosome aberrations | en |
dc.subject | sodium humate | en |
dc.title | Radioprotective properties of sodium humate in radiation-induced mutagenesis in cultured lymphocytes of thyroid cancer patients | en |
dc.type | Article | en |